Form 4: Voyager Therapeutics Grants Equity to COO & CBO Swartz

Voyager Therapeutics, Inc. has awarded significant equity compensation to its Chief Operating Officer and Chief Business Officer, Robin Swartz.

Summary

• Robin Swartz, COO & CBO of Voyager Therapeutics, Inc. (VYGR), was granted 45,000 restricted stock units (RSUs) and 210,000 stock options on February 6, 2026.
• The RSUs were awarded under the company's 2025 Stock Incentive Plan and represent the right to receive one share of common stock upon vesting.
• The RSU award vests over three years, with 1/3rd vesting on the one-year anniversary of the grant date (February 6, 2026) and an additional 1/3rd vesting at the end of each successive one-year period thereafter, subject to continued service.
• The stock options were also issued pursuant to the 2025 Stock Incentive Plan, with an exercise price of $3.68 per share and an expiration date of February 6, 2036.
• The stock options vest over four years, with 1/48th vesting on the one-month anniversary of the grant date (February 6, 2026) and an additional 1/48th vesting at the end of each successive one-month period thereafter, subject to continued service.
• Following these transactions, Robin Swartz beneficially owns 214,647 shares of common stock and 210,000 derivative securities (stock options).

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive development, reflecting standard executive compensation practices that align management incentives with long-term shareholder value, without indicating any immediate operational changes or financial distress.

Positives

• The equity grants align the interests of a key executive, Robin Swartz, with those of shareholders, incentivizing long-term performance and retention.
• The vesting schedules for both RSUs (three years) and stock options (four years) promote sustained commitment from the COO & CBO.

Negatives

• The issuance of new shares upon vesting and exercise of these awards could lead to a degree of future share dilution for existing shareholders, though this is a standard aspect of equity compensation plans.

Risks

• The vesting of both the restricted stock units and stock options is subject to Robin Swartz's continued service with Voyager Therapeutics, Inc.

Future Outlook

The equity grants establish a long-term incentive structure for Robin Swartz, with RSUs vesting over three years and stock options vesting over four years, contingent on continued employment. This indicates a strategic focus on retaining key management and aligning their performance with future company growth.

Industry Context

StockSavvy.ai notes that equity compensation, including restricted stock units and stock options, is a standard practice in the biotechnology and pharmaceutical industries to attract, retain, and incentivize executive talent. This filing reflects a routine compensation event for a key executive at Voyager Therapeutics, Inc., a company focused on gene therapies.

Comparison to Industry Standards

• The use of both RSUs and stock options for executive compensation is a common practice across the biotech sector, similar to compensation structures seen at companies like Sarepta Therapeutics or Alnylam Pharmaceuticals, which often blend immediate value (RSUs) with long-term upside potential (options).
• The multi-year vesting schedules (3-4 years) are typical for executive equity awards in the industry, designed to ensure long-term commitment and align executive interests with shareholder value creation over several fiscal periods.

Stakeholder Impact

• Shareholders: Potential future dilution from the exercise and vesting of equity awards, but also increased alignment of executive interests with shareholder value.
• Employees (specifically Robin Swartz): Significant long-term incentive and compensation tied to company performance and continued service.

Next Steps

• The RSUs will begin vesting on February 6, 2027, with subsequent vesting annually thereafter.
• The stock options will begin vesting on March 6, 2026 (one-month anniversary of grant), with subsequent vesting monthly thereafter.
• Robin Swartz will continue in the role of COO & CBO, subject to continued service for vesting conditions.

Key Dates

Recommendation

This Form 4 filing details routine executive equity compensation and does not contain information that would significantly alter the fundamental investment thesis for Voyager Therapeutics. While it indicates continued executive alignment, it lacks operational or financial performance data to warrant a change in recommendation. Investors should consider this as an expected corporate governance event rather than a catalyst for immediate stock price movement.

Keywords

Voyager Therapeutics, VYGR, Robin Swartz, Restricted Stock Units, RSUs, Stock Options, Equity Compensation, Insider Transaction, Executive Compensation, Form 4, SEC Filing